{"entity":{"id":"bp2202","kind":"drug","name":"BP2202","aka":[],"tldr":"BP2202 is an experimental iPS cell-derived CAR-iNKT cell therapy from BrightPath Biotherapeutics, in phase 1 trials for relapsed or refractory multiple myeloma.","summary":"BP2202 is an iPS cell-derived CAR-iNKT cell therapy (allogeneic) from BrightPath Biotherapeutics. An off-the-shelf allogeneic CAR therapy using NKT cells regenerated from iPS cells, targeting BCMA on myeloma cells. Its furthest stage is phase 1, for relapsed or refractory multiple myeloma. ClinicalTrials.gov registers it in one study linked below. US phase 1 NCT07667868 not yet recruiting (registry, 3 Nov 2026). FDA orphan drug designation July 2025 per company page. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"BrightPath Biotherapeutics: brightpathbio.com","url":"https://www.brightpathbio.com/pipeline/bp2202.html"},{"label":"BrightPath Biotherapeutics: brightpathbio.com","url":"https://www.brightpathbio.com/pipeline/bp2202.html"},{"label":"BrightPath Biotherapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07667868"},{"label":"ClinicalTrials.gov: trials of BP2202","url":"https://clinicaltrials.gov/search?intr=BP2202"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":["bcma"],"drugs":[],"companies":["brightpath-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07667868"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BP2202","modality":"iPS cell-derived CAR-iNKT cell therapy (allogeneic)","mechanism":"An off-the-shelf allogeneic CAR therapy using NKT cells regenerated from iPS cells, targeting BCMA on myeloma cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bp2202/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"company":[{"id":"brightpath-biotherapeutics","kind":"company","name":"BrightPath Biotherapeutics","route":"/companies/brightpath-biotherapeutics/"}],"trial":[{"id":"nct07667868","kind":"trial","name":"A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07667868/"}]}}